Related Experiment Video
Updated: Feb 17, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling
Ying Chen1, Jing Zhao1, Dengzhe Li1
1Department of Hematology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, China.
Purpose:
Tripartite-motif-containing protein 56 (TRIM56) has been found to exhibit a broad antiviral activity, depending upon E3 ligase activity. Here, we attempted to evaluate the function of TRIM56 in multiple myeloma (MM) and its underlying molecular basis.
Materials And Methods:
TRIM56 expression at the mRNA and protein level was measured by qRT PCR and western blot analysis. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry analysis was performed to investigate the effect of TRIM56 on MM cell proliferation and apoptosis. The concentrations of interferon (IFN)-β, interleukin (IL)-6, and tumor necrosis factor-α in MM cell culture supernatants were detected with respective commercial ELISA kits. Western blot was employed to determine the effect of TRIM56 on toll-like receptor 3 (TLR3)/toll-IL-1 receptor (TIR) domain-containing adaptor inducing IFN-β (TRIF) signaling pathway.
Results:
TRIM56 expression was prominently decreased in MM cells. Poly (dA:dT)-induced TRIM56 overexpression in U266 cells suppressed proliferation, induced apoptosis, and enhanced inflammatory cytokine production, while TRIM56 knockdown improved growth, diminished apoptosis, and inhibited inflammatory cytokine secretion in RPMI8226 cells. Moreover, TRIM56 knockdown blocked TLR3 signaling pathway. Furthermore, poly (I:C), a TLR3 agonist, markedly abolished TRIM56 depletion-induced increase of proliferation, decrease of apoptosis, and reduction of inflammatory factor in MM cells.
Conclusion:
TRIM56 may act as a tumor suppressor in MM through activation of TLR3/TRIF signaling pathway, contributing to a better understanding of the molecular mechanism of TRIM56 involvement in MM pathogenesis and providing a promising therapy strategy for patients with MM.
Insights
Tripartite-motif-containing protein 56 (TRIM56) acts as a tumor suppressor in multiple myeloma (MM). Its activation of the TLR3/TRIF pathway inhibits MM cell growth and promotes apoptosis, offering a potential therapeutic strategy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tripartite-motif-containing protein 56 (TRIM56) possesses known broad-spectrum antiviral properties linked to its E3 ligase activity.
- The specific role and molecular mechanisms of TRIM56 in multiple myeloma (MM) pathogenesis remain largely unexplored.
Purpose of the Study:
- To investigate the functional role of TRIM56 in multiple myeloma (MM).
- To elucidate the underlying molecular mechanisms by which TRIM56 influences MM cell behavior and the associated signaling pathways.
Main Methods:
- Quantitative real-time PCR and Western blot were used to assess TRIM56 expression levels in MM cells.
- Cell proliferation and apoptosis were evaluated using MTT assays and flow cytometry.
- Interferon-beta (IFN-β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels were quantified via ELISA.
- The impact of TRIM56 on the toll-like receptor 3 (TLR3)/toll-IL-1 receptor (TIR) domain-containing adaptor inducing IFN-β (TRIF) signaling pathway was analyzed by Western blot.
Main Results:
- TRIM56 expression was significantly reduced in multiple myeloma cells.
- Overexpression of TRIM56 in U266 cells suppressed proliferation, induced apoptosis, and increased inflammatory cytokine production.
- Knockdown of TRIM56 in RPMI8226 cells promoted cell growth, reduced apoptosis, and inhibited inflammatory cytokine secretion.
- TRIM56 knockdown impaired the TLR3 signaling pathway, which was partially restored by TLR3 agonist poly (I:C).
Conclusions:
- TRIM56 functions as a tumor suppressor in multiple myeloma.
- The tumor-suppressive activity of TRIM56 is mediated through the activation of the TLR3/TRIF signaling pathway.
- TRIM56 represents a potential therapeutic target for multiple myeloma treatment.
Related Concept Videos
Abnormal Proliferation
TGF - β Signaling Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

